Skip to main content

Table 1 Baseline demographics, illness history, and baseline illness severity

From: Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

  Placebo Olanzapine
  (N = 52) (N = 104)
Female gender, n (%) 27 (51.9) 63 (60.6)
Age in years, mean (SD) 36.3 (9.5) 40.0 (11.0)
Age in years at onset of BD, mean (SD) 29.1 (8.8) 33.1 (10.9)
Prior episodes, mean (SD)   
 Manic 3.02 (3.07) 3.32 (4.46)
 Depressive 3.77 (3.35) 4.54 (5.69)
 Mixed 0.23 (0.70) 0.13 (0.48)
Weight in kg, mean (SD) 64.02 (12.14) 59.04 (12.35)
Illness severity scores, mean (SD)   
 MADRS total 28.62 (8.01) 29.00 (6.15)
 YMRS total 0.85 (1.32) 0.88 (1.32)
 HAMD-17 total 22.69 (4.08) 23.10 (3.78)
 CGI-BP   
  Depression 4.23 (0.73) 4.35 (0.75)
  Mania 1.02 (0.14) 1.03 (0.17)
  Bipolar 4.10 (0.87) 4.17 (0.86)
  1. Abbreviations: BD = bipolar disorder; CGI-BP = Clinical Global Impressions-Bipolar Version Severity of Illness; HAMD-17 = Hamilton Depression Rating Scale-17 items; MADRS = Montgomery-Åsberg Depression Rating Scale; SD = standard deviation; YMRS = Young Mania Rating Scale.
\